Immix Biopharma (IMMX) Liabilities and Shareholders Equity (2020 - 2026)

Immix Biopharma has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $95.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 381.68% year-over-year to $95.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $236.4 million (up 144.14% YoY) and the FY2025 annual result came in at $104.8 million, up 356.86% from the prior year.
• Liabilities and Shareholders Equity retreated to $95.8 million in Q1 2026 per IMMX's latest filing, from $104.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $104.8 million in Q4 2025 and troughed at $13.2 million in Q1 2023.
• A 5-year average of $30.0 million and a median of $20.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity plunged 45.78% in 2025, then jumped 381.68% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $14.9 million in 2022, then soared by 33.65% to $19.9 million in 2023, then grew by 15.17% to $22.9 million in 2024, then soared by 356.86% to $104.8 million in 2025, then dropped by 8.61% to $95.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $95.8 million, $104.8 million, and $20.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.